Brought to you by 
Series A brings AMD drug developer Ophthotech $36mm
24 Feb 2023
Executive Summary
Ophthotech (eye therapeutics) has raised $36mm in its Series A financing. SV Life Sciences led the round and was joined by other investors including HBM BioVentures and Novo AS.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings AMD drug developer Ophthotech $36mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice